- Email: [email protected]
Cancer Letters special issue hepatobiliary cancer featuring the guest editor
ARTICLE IN PRESS Cancer Letters ■■ (2016) ■■
Contents lists available at ScienceDirect
Cancer Letters j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / c a n l e t
Editorial
Cancer Letters special issue hepatobiliary cancer featuring the guest editor
Dr. Hongyang Wang received resident physician training specializing in gastroenterology in Changzheng Hospital of Shanghai, China. She subsequently studied clinical chemistry and completed her doctor degree at Ulm University, Germany (1992). In 1995, she received a post-doc training in Molecular Biology at Max-Planck Institute of Biochemistry, Germany. In the following three years, as a principal investigator, Dr. Wang conducts research on signal transduction of tumors. In 1997, Dr. Wang returned to Eastern Hepatobiliary Surgery Hospital, China, where she established the laboratory on signal transduction. She pioneered signal transduction research in China. Dr. Wang was selected as a member of Chinese Academy of Engineering. Later, she was selected as a member of the Third World Academy of Sciences in 2011. Devoting to the research of hepatocellular carcinoma (HCC), Dr. Wang has authored more than 180 publications. Additionally, 11
patents of hers have been warranted, including 2 international authorizations. Dr. Wang currently serves as the director of National Centre for Liver Cancer of China, and the director of International Cooperation Laboratory on Signal Transduction in Shanghai Eastern Hepatobiliary Surgery Hospital, China. She is the chief of Department of Health of the National Natural Science Foundation of China (NSFC). This foundation is the principle foundation agency of medical research in China. Dr. Wang’s research focuses on prevention, diagnosis and treatment of liver cancer in China. Her research team in the National Centre for Liver Cancer is interested in molecular mechanisms and translational medicine research of tumors. They have made major contributions to molecular mechanisms of carcinogenesis and signaling network regulations of liver cancer. In 2015, as an invited speaker, Dr. Wang gave a speech titled “Heterogeneity of Hepatocellular Carcinoma—from Bench to Bedside” at the 106th annual meeting of American Association for Cancer Research (AACR) in Philadelphia, USA. As a co-chair, she will organize the upcoming 3rd Cold Spring Harbor Asia (CSHA) Conference on liver diseases and cancer, to be held on April 25–29, 2016, in Suzhou, China.
a
b
Hongyang Wang a,b,* National Center for Liver Cancer, Shanghai, China
International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China * Tel.: +86 21 81875361. E-mail address: [email protected]
http://dx.doi.org/10.1016/j.canlet.2016.01.029 0304-3835/© 2016 Elsevier Ireland Ltd. All rights reserved.
Please cite this article in press as: Hongyang Wang, Cancer Letters (2016), doi: 10.1016/j.canlet.2016.01.029
Contents lists available at ScienceDirect
Cancer Letters j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / c a n l e t
Editorial
Cancer Letters special issue hepatobiliary cancer featuring the guest editor
Dr. Hongyang Wang received resident physician training specializing in gastroenterology in Changzheng Hospital of Shanghai, China. She subsequently studied clinical chemistry and completed her doctor degree at Ulm University, Germany (1992). In 1995, she received a post-doc training in Molecular Biology at Max-Planck Institute of Biochemistry, Germany. In the following three years, as a principal investigator, Dr. Wang conducts research on signal transduction of tumors. In 1997, Dr. Wang returned to Eastern Hepatobiliary Surgery Hospital, China, where she established the laboratory on signal transduction. She pioneered signal transduction research in China. Dr. Wang was selected as a member of Chinese Academy of Engineering. Later, she was selected as a member of the Third World Academy of Sciences in 2011. Devoting to the research of hepatocellular carcinoma (HCC), Dr. Wang has authored more than 180 publications. Additionally, 11
patents of hers have been warranted, including 2 international authorizations. Dr. Wang currently serves as the director of National Centre for Liver Cancer of China, and the director of International Cooperation Laboratory on Signal Transduction in Shanghai Eastern Hepatobiliary Surgery Hospital, China. She is the chief of Department of Health of the National Natural Science Foundation of China (NSFC). This foundation is the principle foundation agency of medical research in China. Dr. Wang’s research focuses on prevention, diagnosis and treatment of liver cancer in China. Her research team in the National Centre for Liver Cancer is interested in molecular mechanisms and translational medicine research of tumors. They have made major contributions to molecular mechanisms of carcinogenesis and signaling network regulations of liver cancer. In 2015, as an invited speaker, Dr. Wang gave a speech titled “Heterogeneity of Hepatocellular Carcinoma—from Bench to Bedside” at the 106th annual meeting of American Association for Cancer Research (AACR) in Philadelphia, USA. As a co-chair, she will organize the upcoming 3rd Cold Spring Harbor Asia (CSHA) Conference on liver diseases and cancer, to be held on April 25–29, 2016, in Suzhou, China.
a
b
Hongyang Wang a,b,* National Center for Liver Cancer, Shanghai, China
International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China * Tel.: +86 21 81875361. E-mail address: [email protected]
http://dx.doi.org/10.1016/j.canlet.2016.01.029 0304-3835/© 2016 Elsevier Ireland Ltd. All rights reserved.
Please cite this article in press as: Hongyang Wang, Cancer Letters (2016), doi: 10.1016/j.canlet.2016.01.029